Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)
Chris Parker, René Horsleben Petersen, Adrian Cook, Noel W. Clarke, Charles Catton, William Cross, Howard Kynaston, Wendy R. Parulekar, Raj Persad, Fred Saad, L. Bower, G. Durkan, John Logue, C. Maniatis, D. Noor, Heather Payne, J R Anderson, Amit Bahl, Faizan Bashir, David Bottomley, Klaus Brasso, Lisa Capaldi, Christina Lee Chung, Peter Cooke, James F. Donohue, Ben Eddy, Catherine Heath, Alastair Henderson, Ann Henry, R. Jaganathan, Henrik Jakobsen, Nicholas D. James, J. Joseph, Kathryn Lees, J.F. Lester, Henriette Lindberg, Adel Makar, Stephen Morris, Nikhil Babu Oommen, Peter Ostler, Louise Owen, Prashant Patel, A. Pope, R. Popert, Rakesh Raman, Vijay Ramani, Martin Andreas Røder, Ian Sayers, Matthew Simms, Venkat Srinivasan, S.K. Sundaram, Kathryn Tarver, Anna Tran, Paula Wells, J. Wilson, Anjali Zarkar, Mahesh Parmar, Matthew R. Sydes
Abstract
BACKGROUND: The optimal timing of radiotherapy (RT) after radical prostatectomy for prostate cancer has been uncertain. RADICALS-RT compared efficacy and safety of adjuvant RT versus an observation policy with salvage RT for prostate-specific antigen (PSA) failure. PATIENTS AND METHODS: RADICALS-RT was a randomised controlled trial enrolling patients with ≥1 risk factor (pT3/4, Gleason 7-10, positive margins, preoperative PSA≥10 ng/ml) for recurrence after radical prostatectomy. Patients were randomised 1:1 to adjuvant RT ('Adjuvant-RT') or an observation policy with salvage RT for PSA failure ('Salvage-RT') defined as PSA≥0.1 ng/ml or three consecutive rises. Stratification factors were Gleason score, margin status, planned RT schedule (52.5 Gy/20 fractions or 66 Gy/33 fractions) and treatment centre. The primary outcome measure was freedom-from-distant-metastasis (FFDM), designed with 80% power to detect an improvement from 90% with Salvage-RT (control) to 95% at 10 years with Adjuvant-RT. Secondary outcome measures were biochemical progression-free survival, freedom from non-protocol hormone therapy, safety and patient-reported outcomes. Standard survival analysis methods were used; hazard ratio (HR)<1 favours Adjuvant-RT. RESULTS: Between October 2007 and December 2016, 1396 participants from UK, Denmark, Canada and Ireland were randomised: 699 Salvage-RT, 697 Adjuvant-RT. Allocated groups were balanced with a median age of 65 years. Ninety-three percent (649/697) Adjuvant-RT reported RT within 6 months after randomisation; 39% (270/699) Salvage-RT reported RT during follow-up. Median follow-up was 7.8 years. With 80 distant metastasis events, 10-year FFDM was 93% for Adjuvant-RT and 90% for Salvage-RT: HR=0.68 [95% confidence interval (CI) 0.43-1.07, P=0.095]. Of 109 deaths, 17 were due to prostate cancer. Overall survival was not improved (HR=0.980, 95% CI 0.667-1.440, P=0.917). Adjuvant-RT reported worse urinary and faecal incontinence 1 year after randomisation (P=0.001); faecal incontinence remained significant after 10 years (P=0.017). CONCLUSION: Long-term results from RADICALS-RT confirm adjuvant RT after radical prostatectomy increases the risk of urinary and bowel morbidity, but does not meaningfully improve disease control. An observation policy with salvage RT for PSA failure should be the current standard after radical prostatectomy. TRIAL IDENTIFICATION: RADICALS, RADICALS-RT, ISRCTN40814031, NCT00541047.